Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
Veradermics reported positive topline results from its Phase 2/3 trial of oral VDPHL01 in male pattern hair loss, with the drug meeting all primary and key secondary endpoints with high statistical significance. Treatment with VDPHL01 resulted in robust hair growth, with increases of 30.3 and 33.0 hairs/cm² for once-daily and twice-daily dosing respectively, compared to 7.3 hairs/cm² for placebo at Month 6.
Key figures
- Drug Name
- VDPHL01
- Phase Of Trial
- Phase 2/3
- Hair increase qd
- 30.3 hairs/cm²
- Hair increase bid
- 33.0 hairs/cm²
- Patients enrolled
- 519
- Hair increase placebo
- 7.3 hairs/cm²
- Patient improvement qd
- 79.3%
- Patient improvement bid
- 86.0%
- Patient improvement placebo
- 35.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.